VDC Platform (Lead Candidate)

About Aura Biosciences

Aura Biosciences is leveraging its proprietary Virus-Like Drug Conjugate (VDC) platform to develop targeted therapies for solid tumors, with an initial focus on ocular and urologic oncology. The company's lead program targets choroidal melanoma, a rare cancer where current radiotherapy treatments often lead to severe vision loss and poor long-term survival. Aura's approach aims to transform cancer treatment by enabling precise tumor targeting while sparing healthy tissue, potentially offering a vision-preserving alternative to existing standards of care.

Therapeutic Areas